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Abstract 
The healing process of the skin is a dynamic procedure mediated through a complex feedback of 
growth factors secreted by a variety of cells types. Despite the most recent advances in wound 
healing management and surgical procedures, these techniques still fail up to 50%, so cellular 
therapies involving mesenchymal stem cells (MSCs) are nowadays a promising treatment of skin 
ulcers which are a cause of high morbidity. The MSCs modulate the inflammatory local response 
and induce cell replacing, by a paracrine mode of action, being an important cell therapy for the 
impaired wound healing. The local application of human MSCs (hMSCs) isolated from the umbilical 
cord Wharton’s jelly together with a poly(vinyl alcohol) hydrogel (PVA) membrane, was tested to 
promote wound healing in two dogs that were referred for clinical examination at UPVET Hos-
pital, showing non-healing large skin lesions by the standard treatments. The wounds were infil-
trated with 1000 cells/µl hMSCs in a total volume of 100 µl per cm
2 of lesion area. A PVA 
membrane was applied to completely cover the wound to prevent its dehydration. Both animals 
after the treatment demonstrated a significant progress in skin regeneration with decreased extent 
of ulcerated areas confirmed by histological analysis. The use of Wharton’s jelly MSCs associated 
with a PVA membrane showed promising clinical results for future application in the treatment of 
chronic wounds in companion animals and humans. 
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Introduction 
Proper cutaneous wound repair requires a good 
coordination of inflammation, neovascularisation, 
extracellular matrix (ECM) formation and epitheliali-
sation. When skin is severely damaged, the ability to 
repair itself is limited resulting in hypertrophic scars, 
so-called keloid scar, and consequent non-healing, or 
ulceration, or excessive scar contraction of the wound. 
Traditional therapies for treatment of chronic wound 
include surgical debridement, minimization of local 
bacterial multiplication; pressure off-loading, nega-
tive-pressure therapy, skin grafting and reconstruc-
tive tissue flaps. Despite the most recent advances in 
wound healing management and surgical procedures, 
these techniques still fail up to 50% [1]. The difficulty 
of the healing process of chronic wounds might be 
due to local ischemia, reperfusion injury, bacterial 
infection, or aging resulting in chronic inflammation 
[2]. Also in non-healing wounds the cell pool is in-
trinsically impaired and might demonstrate increased 
senescence and decreased response to growth factors 
[3, 4]. MSCs present high plasticity, proliferative and 
differentiation capacity together with important im-
munosuppressive properties and low immunogenic-
ity due to a decreased Human Leucocyte Antigen 
(HLA) class II expression [5-9], representing a prom-
ising cellular system to improve wound healing.  
There are many studies involving mice and hu-
mans which have consistently demonstrated en-
hanced wound repair following treatment by infiltra-
tion or lesion local application, with bone mar-
row-derived MSCs [10, 11]  or MSCs from other 
sources, like the umbilical cord blood (UCB) [12] and 
adipose tissue [13] Analysis of the mechanical prop-
erties of treated wounds revealed that administration 
of MSCs not only accelerated wound closure but also 
enhanced wound repair quality, resulting in repaired 
tissue with increase tensile strength. This effect is 
thought to be secondary to an increased in collagen 
composition within the repaired tissue [14].  
MSCs isolated from the umbilical cord matrix 
(Wharton’s jelly) have many advantages, such as, 
shorter population doubling time; can be easily cul-
tured in plastic flasks, are well tolerated by the re-
ceptor immune system, so transplantation into 
non-immune-suppressed animals does not induce 
acute rejection, have anticancer properties [7]  and 
most important are not tumorigenic [15, 16]. For these 
reasons we believe that cellular therapy using MSCs 
from the Wharton´s jelly in chronic wounds treatment 
is a promising field of investigation with great interest 
in Regenerative Medicine.  
The MSCs delivery method is also very im-
portant and some authors used subcutaneous injec-
tion, systemic injection, intradermal injection and 
topical applications or combinations of these routes 
[17, 18]. The clinical effectiveness of MSCs-based 
therapy is dependent on the number of cells delivered 
and survival, so it is important to optimize the deliv-
ery procedure. Falanga and collaborators utilized a 
fibrin spray system to topically administer autologous 
MSCs to non-healing lower extremity wounds in 
human subjects detecting considerable clinical im-
provements  [18,19]. Hydrogels, as new generation 
synthetic biomaterials, are being developed at a fast 
speed to be used as three-dimensional extracellular 
microenvironment in order to simulate the regulatory 
characteristics of natural ECMs and ECM-bound 
growth factors, both for therapeutic applications and 
basic biology studies. Although modern synthetic 
biomaterials represent oversimplified mimics of nat-
ural ECMs lacking the essential natural temporal and 
spatial complexity, a growing symbiosis of engi-
neered materials and cell biology, it may eventually 
result in synthetic materials that contain the necessary 
signalling to run through development processes in 
tissue-  and organ-specific differentiation and mor-
phogenesis [20]. 
 This would be ideal for topical application of the 
MSCs demonstrating significant accelerated wound 
closure and improved quality of cutaneous regenera-
tion with an increased number of hair follicles and 
sebaceous glands when compared to intradermal in-
jection strategies [18]. 
On the other hand based on the nature of 
wounds and healing approaches, several materials 
have been developed for use in wound dressings and 
bandages [21]. The crucial requirements of an ideal 
wound dressing includes: pain control, easy replace-
ment, transparency to facilitate the healing follow up, 
absorption and prevention of body fluid losses, ex-
isting barrier against bacteria, oxygen (O2) permeabil-
ity, easy handling, and drug dosage control. Poly-
saccharides based hydrogels are good materials for 
wound dressings since they can adhere to the wound 
side protecting it from external milieu. They are 
transparent, so the clinical observation of wound site 
and healing process can be easily monitored; they also 
can be tailored into various shapes and sizes, they are 
permeable to O2 and carbon dioxide (CO2) but prevent 
the passage of microorganism [15].  
The  PVA is a water-soluble synthetic polymer 
and is prepared via the hydrolysis of 
poly(vinyl-acetate), in which the acetate groups are 
replaced by hydroxyls. In medical devices, PVA is 
being used as a biomaterial due to its biocompatibil-
ity, swelling properties, bio-adhesive characteristics, 
and for being non-toxic and non-carcinogenic [6, 22]. 
PVA may mimic the regulatory characteristics of nat-
ural ECMs and ECM-bound growth factors, both in Int. J. Med. Sci. 2014, Vol. 11 
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clinical applications and in basic biology studies [20]. 
The two patients referred to UPVET Hospital – 
ICBAS, University of Porto, Portugal, were previously 
treated with standard treatment protocols with no 
clinical improvement; and in both animals it was not 
possible to perform free grafts or rotational flaps. So, 
it was decided to use human MSCs (hMSCs) from 
Wharton’s jelly therapy associated to the application 
of a PVA membrane. The results are presented and 
discussed here. 
Materials and Methods 
Poly(vynil-alcohol) hydrogel (PVA) 
membranes 
Membranes of PVA (Aldrich, Mowiol 10-98) 
with a thickness of about 1 mm were prepared using a 
casting technique. A 15% (w/v) aqueous solution of 
PVA was used. The membranes were produced by a 
freezing/thawing process consisting in three cycles of 
freezer (-30oC) / incubator (25oC). The membranes 
were hydrated during 2 h before use. 
Cell Culture of human MSCs (hMSCs) from 
Wharton’s jelly umbilical cord, viability and 
karyotype analysis  
Human MSC from Wharton’s jelly UC (hMSCs) 
were purchased from PromoCell GmbH (C-12971, 
lot-number: 8082606.7). Cryopreservated cells were 
cultured and maintained in a humidified atmosphere 
with 5% CO2  at 37ºC. Mesenchymal Stem Cell Me-
dium (PromoCell, C-28010) was replaced every 48 
hours. At 90% confluence, cells were harvested with 
0.25% trypsin with EDTA (Gibco) and passed into a 
new flask for further expansion. hMSCs at a concen-
tration of 2500 cell/ml were cultured and after 24 
hours cells exhibited 30-40% confluence. Mesenchy-
mal Stem Cell Medium (PromoCell, C-28010) was 
replaced every 48 hours. The phenotype, the cell 
morphology, adherence rate and viability of the 
hMSCs was assessed by PromoCell by rigid quality 
control tests. Each cell lot was characterized by flow 
cytometry analysis for a comprehensive panel of 
markers [23]. The hMSCs established PromoCell cell 
line exhibited a mesenchymal-like shape with a flat 
and polygonal morphology in culture. During expan-
sion the cells became long spindle-shaped and colo-
nized the whole culturing surface (Figure 1). At 90% 
confluence, cells were harvested with 0.25% trypsin 
with EDTA (Gibco) and a suspension of 1000cells/µl 
was prepared in insulin syringes to facilitate the sur-
gical procedure. The hMSCs infiltration was per-
formed in a total volume of 100 µl per cm2 of lesion 
area. Chromosome analysis on the hMSCs before in 
vivo application was carried out between passages 4 
and 5, as previously described [23]. Chromosome 
analysis was performed by one scorer on 20 Giem-
sa-stained metaphases. Each cell was scored for 
chromosome number. Routine chromosome 
G-banding analysis was also carried out for determi-
nation of the karyotype. Intracellular free Ca2+ con-
centration ([Ca2+]i) was measured in Fura-2-loaded 
cells by using dual wavelength spectrofluorometry as 
previously described [23, 24]. The measurements were 
performed on undifferentiated hMSCs cultured on 
PVA membrane discs after confluence was obtained, 
in order to correlate the hMSCs ability to expand and 
survival capacity in the presence of the biomaterial. 
The application of the hMSCs isolated from the um-
bilical cord Wharton’s jelly in dogs is possible without 
inducing immunessupression, as previously referred. 
 
 
Figure 1 - Undifferentiated human mesenchymal stem cells (hMSCs), from human 
umbilical cord Wharton’s jelly, exhibiting a star-like shape with a flat morphology 
(Magnification: 100x). 
 
Physical examination and surgical procedure 
The clinical cases concerning two dogs were re-
ferred for examination at UPVET Hospital – ICBAS, 
University of Porto, Portugal. In clinical case 1, a 2 
years old, 32 kg neutered male mixed breed dog, 
presented a chemical burn injury with a 16-month 
history of clinical presentation and evolution and 
without any healing response to several and previous 
standard treatments. The lesion involved the left tho-
racic and abdominal wall and consisted of two main 
central and ulcerated areas, measuring 7.0x2.0 cm and 
3x3 cm and surrounded by an exuberant fibrous scar 
(Figure 2A). 
In the clinical case 2, a 5 years old, 34 kg spayed 
female mixed breed dog, presented a similar but 
smaller lesion, with a 24-month history of evolution 
and also refractory to the conventional treatments 
previously instituted. The ulcerated lesion was local-Int. J. Med. Sci. 2014, Vol. 11 
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ized in the sacro-iliac region and measured 6x5 cm, 
presenting peripheral fibrosis (Figure 3A). The cause 
of the injury was unknown. After a complete physical 
examination, the only abnormal finding in both ani-
mals was the deep and extensive skin ulcerated le-
sions affecting the epidermal and dermal layers. By 
the time of the surgery (pre-treatment biopsy), both 
animals were submitted to a skin biopsy performed 
with a scalpel blade number 23. Collected tissues were 
then fixed in 10% buffered formalin, paraf-
fin-embedded, 3-µm thick cut and stained with hae-
matoxylin and eosin (HE) for histological examina-
tion. 
 
 
 
Figure 2 – In clinical case 1, it can be observed an extensive chemical burn injury in the left thoracic wall with two central ulcerated areas presenting approximately 7cmx2cm 
and 3cmx3cm surrounded by an extensive fibrous scar (A). Surgical biopsy and wound debridement (B). PVA membrane application over the lesion area, after the hMSCs 
intradermal infiltration (C). Moisture retentive bandage over the PVA membrane to prevent lesion dissecation (D, E). Complete cicatrization 2 months after human hMSCs local 
application (F). 
 
 
Figure 3 – In clinical case 2 the lesion was localized in the sacro-iliac region and measured approximately 6cmx5cm, with a central ulcerated and necrotic area presenting 
peripheral fibrosis. The lesion was of unknown cause (A). Surgical biopsy and wound debridement (B). Intradermal hMSCs application (C). Moisture retentive bandage over the 
PVA membrane to prevent lesion dissecation (D, E). Complete cicatrization 2 months after human hMSCs local application (F). 
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Both animals were previously subjected to 
standard clinical treatments for inducing healing by 
second intention, like healing ointments, hydrogel 
bandages and sugar bandages. In clinical case 1, an 
improvement occurred (in the area correspondent to 
the fibrosis area) until cicatrization process stopped 
without complete closure of the wound. The wound 
remained without any sign of improvement for about 
16 months. 
For the hMSCs application, both animals were 
pre-medicated with morphine (0,5mg/kg) and diaz-
epam (0,2mg/kg), induced with propofol (4mg/kg) 
and maintained with isoflorane 2%. The affected area 
was surgically prepared. The edges of the wound 
were debrided (Figure 2B and Figure 3B) and the un-
differentiated hMSCs from Wharton's jelly of human 
umbilical cord, previously isolated and expanded in 
vitro were locally infiltrated at a concentration of 1000 
cells/µl in culture medium (Figure 1, Figure 3C). The 
hMSCs infiltration was performed in a total volume of 
100 µl per cm2 of lesion area. Methylprednisolone was 
intravenously administered (Solu-medrol 125®, Pfiz-
er, 1 mg / kg). Antibiotherapy was performed in both 
patients with Enrofloxacin 5 mg/kg once a day for 15 
days. Finally, a sterile PVA membrane was applied to 
prevent desiccation of the wound (Figure 2C and 
Figure 3D), and a moisture-retentive dressing was 
applied over it and changed twice a day until day 3 
after surgery (Figure 2D, Figure 2E, Figure 3E). Af-
terwards, the wound dressing was changed daily for 
the  next 15 days. After this period, the PVA mem-
branes were removed and non-adherent dressings 
were applied over the lesion area and daily changed 
during 10 more days. After complete cicatrization (2 
months after the surgery) a second skin biopsy was 
performed to the clinical case 1, in attempt to evaluate 
the progress of the lesion. Unfortunately the second 
skin biopsy was not performed in clinical case 2, since 
the owners did not authorized it. 
Results  
hMSCs cell culture, viability and karyotype 
analysis 
Undifferentiated hMSCs from umbilical cord 
Wharton’s jelly exhibited a normal star-like shape 
with a flat morphology in culture (Figure 1). A total of 
20 Giemsa-stained metaphases of these cells, were 
analysed for numerical aberrations. Sporadic, 
non-clonal aneuploidy was found in 1 cell (45 chro-
mosomes). The other 19 metaphases had 46 chromo-
somes. The karyotype was determined in a com-
pletely analysed G-banding metaphase and no struc-
tural alterations were found. The karyotype analysis 
performed demonstrated once again, like in previous 
published experimental work [23], that this cell line 
has not neoplastic characteristics and is stable during 
the cell culture procedures in terms of number and 
structure of the somatic and sexual chromosomes. 
Results obtained from epifluorescence technique 
[Ca2+]i  measurements with the undifferentiated 
hMSCs corresponded to cells that did not begin the 
apoptosis process. The undifferentiated hMSCs cul-
tured on PVA membranes reached confluence and 
exhibited a normal star-like shape with a flat mor-
phology in culture. According to these results, it is 
reasonable to conclude that PVA membranes are a 
viable substrate for undifferentiated human MSCs 
adhesion, and expansion (Figure 1). 
Clinical follow-up and Histological 
Examination 
There were no clinical complications in the 
post-operative period and after 2 months a complete 
epithelialisation was observed in both cases (Figure 2F 
and Figure 3F). The animals remained without any 
discomfort, pain or prurience throughout this period.  
Prior to the hMSCs-based therapy with a PVA 
membrane procedure, in clinical case 1, microscopi-
cally, the affected skin presented an extensive and 
irregular epidermal hyperplasia, with various or-
thokeratotic hyperkeratosis and parakeratosis foci. 
Several and multifocal areas of ulceration covered by 
serocellular crusts containing numerous clusters of 
bacteria, associated with large amount of inflamma-
tory infiltrate, consisting predominantly of neutro-
phils and fewer lymphocytes were also observed. The 
dermis displays images of exuberant fibrosis and 
dermal-epidermal dissociation. It was not possible to 
identify skin appendages (Figure 4A and Figure 4B).  
In clinical case 2, focal epidermal ulceration was 
observed with the histological exam. The dermis was 
constituted in its almost entire length by dense con-
nective tissue showing few nuclei and cells, with the 
presence of various hemorrhage and fibrinoid necro-
sis areas (Figure 5A and Figure 5B). 
By the time of the second biopsy (2 months), in 
clinical case 1, the epidermal showed moderate or-
thokeratotic hyperplasia and presence of multifocal 
serocellular crusts. Areas of dermal fibrosis and ab-
sence of skin appendages were still prominent fea-
tures however, in the superficial dermis, an exuberant 
granulation tissue was noted, rich in active fibroblasts 
and dilated neo-vessels coated by tall columnar en-
dothelium. Moderate amount of diffuse mononuclear 
cell infiltration (macrophages, plasma cells and lym-
phocytes) was also present (Figure 4C and Figure 4D). Int. J. Med. Sci. 2014, Vol. 11 
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Figure 4 - Histopathological findings of clinical case 1 skin biopsy. Before the scaffold application (pre-treatment biopsy), the affected skin presented severe and multifocal areas 
of ulceration (A and B), associated with large amount of inflammatory infiltrate consisting predominantly of neutrophils. The dermis displays images of exuberant fibrosis. It was 
not possible to identify skin appendages. This could be observed using HE and a magnification of 100x (A) and 400x (B). At day 60 after the hMSCs application, the epidermal 
showed signs of re-epithelization presenting orthokeratotic hyperplasia and multifocal serocellular crusts, HE, 40x (C). In the underlying dermis an exuberant granulation tissue 
was noted, with several fibroblasts and dilated neovessels containing neutrophils, HE, 400x (D).  
 
Figure 5 - Histopathological findings of clinical case 2 skin biopsy. Before the scaffold application (pre-treatment biopsy), the dermis was constituted in its almost entire length 
by dense connective tissue showing few nuclei and cells, HE and magnification of 40x (A). Ulceration, hemorrhage and fibrinoid necrosis areas were also observed in the mid- to 
superficial dermis, HE and magnification of 40x (B). 
 
Discussion  
Tissue engineering is a multidisciplinary re-
search field that combines the ideologies of engineer-
ing and life sciences together to develop biological 
substitutes to restore, maintain or improve tissue 
function. Therefore there are emerging cellular thera-
pies as an alternative for organ and tissue transplan-
tation. MSCs have become one of the most interesting 
cells for tissue engineering since these cells present 
high plasticity, proliferative and differentiation ca-
pacity and immunosuppressive properties due to a 
decreased or even absence of HLA class II expression 
[25]. Currently the differentiation potential of MSCs in 
multi-lineage end-stage cells is already proven, and Int. J. Med. Sci. 2014, Vol. 11 
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their potential for treatment of cardiovascular [26], 
neurological [27], musculoskeletal [28], and cutaneous 
[1] diseases is now well established. MSCs can be ob-
tained from many different tissues, including bone 
marrow, adipose tissue, skeletal muscle, umbilical 
cord matrix and blood, placental tissue, amniotic flu-
id, synovial membranes, dental pulp, foetal blood, 
liver and lung [29-34]. These cells are important for 
the Regenerative Medicine field because they have 
anti-inflammatory and immunomodulate properties 
by cytokines and growth factors production [35, 36]. 
As a matter of fact, the therapeutic effects of MSCs are 
due to their ability to repair damage tissue, to their 
capacity of modulating surrounding environment, 
and of activating endogenous progenitor cells [37, 38]. 
Also, several studies have demonstrated that MSCs, 
have a higher chromosomal stability and lower ten-
dency to form tumours and teratomas, compared to 
other stem cells, for instance, embryonic stem cells 
(ESCs) [39-41].  
The local application of hMSCs isolated from the 
umbilical cord Wharton’s jelly together with a PVA 
membrane, was tested to promote wound healing in 
two dogs that were referred for clinical examination at 
UPVET Hospital, showing non-healing large skin 
lesions after standard treatments failure. 
In these two clinical trials, the karyotype analysis 
of the hMSCs cell line derived from the Wharton’s 
jelly locally applied, demonstrated that this cell line 
did not have neoplastic characteristics and was stable 
during the cell culture procedures in terms of number 
and structure of the somatic and sexual chromosomes. 
Also, the results obtained from [Ca2+]i epifluorescence 
measurements performed with hMSCs cultured on 
PVA discs, confirmed that these cells that did not 
begin the apoptosis process and were viable cells. The 
undifferentiated hMSCs in vitro  cultured on PVA 
membranes reached confluence and exhibited a nor-
mal star-like shape with a flat morphology in culture, 
which proved the citocompatibility of this biomateri-
al. According to these results, it is reasonable to con-
clude that PVA membranes are a viable substrate for 
undifferentiated hMSCs adhesion, and multiplication. 
The option to have chosen a physically, instead of the 
chemically, cross-linked PVA membranes aimed to 
avoid releasing of chemical compounds from a classic 
chemical cross-linking technique that could interfered 
with cell behaviour. As reported elsewhere [42], the 
freezing/thawing technique leads to anisotropic mi-
crostructure materials. The processing route chosen in 
this study produced PVA membranes with a struc-
ture, morphology and stability adequate to be used 
with cellular systems like the hMSCs from the umbil-
ical cord Wharton’s jelly.  
The healing process is a complex and dynamic 
phenomenon which normally happens in a very or-
derly and efficient manner in order to restore the an-
atomical continuity and tissue function. The normal 
healing  cascade begins with haemostasis and fibrin 
deposition which leads to an inflammatory cell cas-
cade, characterized by neutrophils, macrophages and 
lymphocytes within the tissue. This is followed by 
attraction and proliferation of fibroblast and collagen 
deposition and finally remodelling by collagen 
cross-linking and scar maturation. If any part of this 
healing sequence is altered, pathologic responses can 
occur, leading to fibrosis and chronic ulcers [43]. In 
some pathological conditions the lesions stay trapped 
in a state of chronic inflammation characterized by 
abundant neutrophil infiltration, as described in clin-
ical case 1 before the hMSCs and PVA application. 
The neutrophils release enzymes responsible for the 
destruction of the connective tissue matrix, for the 
inhibition of important healing factors and are asso-
ciated with reactive oxygen species that cause cell 
damage. When tissues are injured, the fibroblasts 
synthesize collagen which is essential to repair the 
defect and restore the tissue anatomic structure and 
function  [43]. However, if an excessive amount of 
collagen is deposited, the normal anatomical structure 
is lost, function is compromised and fibrosis occurs 
with reduced remodelling, similarly to that seen in 
clinical case 2 before the scaffold application. In both 
described clinical cases, the healing process would 
possible proceed if the inflammation was controlled 
and the wound bed was properly prepared.  
Histological analysis over time of clinical case 1 
indicated that hMSCs-treated wound  showed more 
stable features in the epidermal layer compared with 
day 0, suggesting a more mature epithelium. A 
noteworthy change in the nature of the inflammatory 
infiltrate was recorded: neutrophils were gradually 
replaced by mononuclear cells associated with gran-
ulation tissue formation, suggesting that the classical 
healing sequence was overtaken. It was also observed 
that, by the time of the second biopsy, the treated 
wound was involved by a denser capillary network 
when compared with the biopsy analysis performed 
prior to the scaffold application, suggesting that the 
treatment applied promoted angiogenesis in the 
dermis. These results suggest that in clinical case 1, 
the hMSCs infiltrated in the wound accelerated epi-
dermal and dermal renewal. Despite the absence of 
the second biopsy to confirm the histopathological 
evolution of the lesion, the clinical course of the case 2 
is clearly remarkably since, as you can see in figure 3, 
panel F, the rate of wound closure and 
re-epithelialization was accelerated, the quality and 
strength of the regenerated tissue was improved and 
the visual appearance of the lesion was minimize. All Int. J. Med. Sci. 2014, Vol. 11 
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these evidences, taken together, suggest that the ap-
plication of hMSCs could accelerate wound healing, 
promoting angiogenesis and providing the cells and 
cellular factors needed to create the optimal 
wound-healing microenvironment in canine chronic 
wounds.  
Previous studies showed that MSCs exhibit a 
considerable and important number of trophic func-
tions to enhance tissue regeneration (for review see 
the published work of Jackson et al., 2012 [44]), such 
as modulating the inflammatory response (by regu-
lating the function of the leukocytes present in the 
lesion) and promoting angiogenesis. Once the MSCs 
enter the inflammatory environment due to chemo-
taxis, their immunomodulatory phenotype is acti-
vated by interferon-γ (IFNγ), tumour necrosis factor-α 
(TNFα) and interleukin-1β (IL-1β) [45]. It is also well 
documented the ability of MSCs to regulate T-cell 
recruitment, proliferation and activity [45] and their 
capability of suppressing the proliferation of B cells 
[46] and natural killer cells [47], thereby improving 
the acute immune response to injury [48]. By attenu-
ating the function of these cell types, the MSCs would 
likely reduce the pro-fibrotic responses that can occur 
coincident with prolonged inflammation during 
wound healing [49]. Moreover, some studies reported 
that engrafted MSCs in the wound improved angio-
genesis by exerting a paracrine effect which increases 
levels of angiogenic factors such as angiopoietin-1 and 
vascular endothelial growth factor (VEGF) [50].  
In both clinical cases described, both patients 
were not good candidates to do rotational flaps or free 
grafts since the extension and location of the lesions 
did not allow obtaining healthy skin to transpose and 
the free grafts had very small chance to be successful 
since their irrigation would be very compromised by 
the skin architecture of the surrounding tissues. The 
results of our study reinforced the efficacy of therapy 
with hMSCs on enhancing wound healing in dogs by 
promoting epidermal and dermal regeneration and 
angiogenesis. However, further studies are needed in 
order to investigate if its administration may thus 
represent a novel therapeutic approach and to clini-
cally explore further improvements in canine cuta-
neous wound therapy.  
It was concluded that, in both clinical cases the 
association of hMSCs from Wharton’s jelly of human 
umbilical cord and PVA membrane did not present 
any negative effect and even improved  the wound 
healing, in two clinical cases where the standard 
treatments failed. This cellular therapy associated to a 
PVA membrane should be further investigated in 
order to be applied in the future in veterinary clinical 
practice as in human medicine. 
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